Imidazopyrimidines, potent inhibitors of p38 MAP kinase

…, DE Cavender, GC Olini, B Fahmy, JJ Siekierka

Index: Rupert, Kenneth C.; Henry, James R.; Dodd, John H.; Wadsworth, Scott A.; Cavender, Druie E.; Olini, Gilbert C.; Fahmy, Bohumila; Siekierka, John J. Bioorganic and Medicinal Chemistry Letters, 2003 , vol. 13, # 3 p. 347 - 350

Full Text: HTML

Citation Number: 155

Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.